Compare · ADXS vs NEOS
ADXS vs NEOS
Side-by-side comparison of Advaxis, Inc. (ADXS) and Neos Therapeutics, Inc. (NEOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADXS and NEOS operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- Company
- Advaxis, Inc.
- Neos Therapeutics, Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Latest ADXS
- OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
- Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
- SEC Form 15-12G filed by Advaxis, Inc.
- SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)
- Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 10-K filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
Latest NEOS
- FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC
- FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form 8-K filed by Neos Therapeutics, Inc.
- SEC Form 425 filed by Neos Therapeutics, Inc.
- SEC Form 4: M John Limongelli disposed to the issuer $0 worth of Common Stock (83,015 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Jr. A. James Robinson disposed to the issuer $0 worth of Common Stock (23,453 units at $0.00), decreasing direct ownership by 100% to 0 units